Shimadzu Releases Amyloid MS CL System for Measuring Candidate Substance Potentially Causing Alzheimer’s DiseaseSystem Requires Testing Only a Small Quantity of Blood, which Reduces Burden to Patients July 21, 2021 by / Share This.....LinkedinTwitterFacebookGoogleEmailRelated News: Roche's Elecsys Amyloid Plasma Panel granted…Roche provides update on Alzheimer’s Prevention…Making Nissui Pharmaceutical as a Wholly-Owned…Making Nissui Pharmaceutical as a Wholly-Owned…Wipro GE Healthcare launches its first ‘Made in…World’s Only Instrument Capable of Performing Both…
